We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Topical Nanotechnology Simplifies Skin Disease Diagnosis

By LabMedica International staff writers
Posted on 30 May 2018
Tissue biopsies are necessary for the accurate diagnosis of skin diseases, but their application is limited by the pain, inconvenience, and morbidity experienced by patients, as well as risks of scarring and infection.

Many skin diseases, such as abnormal scars, are typically identified by visual identification of scar lesions; however, a visible scar is already mature, having generated significant newly formed tissue, and is unable to benefit from timely administration of prophylactics.

Scientists at the Nanyang Technological University (Singapore) used NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy. More...
It is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.

NanoFlares are inactive and emission signal remains low. NanoFlares targeting reference genes (i.e., Glyceraldehyde-3-Phosphate Dehydrogenase (GapDH) and noncoding sequences) can be simultaneously employed for signal normalization. Thus, abnormal fibroblasts can be discriminated from non-diseased ones by their fluorescence signal. In this process, NanoFlares maintain their detection properties and molecular specificity following transepidermal and intracellular entry.

Transdermal NanoFlare penetration is the results from their unique nanostructure. They comprise highly packed oligonucleotide strands directionally aligned to cores (comprising a range of different materials, including gold) and even hollow-core nanoparticles. This gives the resultant particles a strong negative surface charge.

NanoFlares are topically applied on the lesion, which penetrate the skin barrier, interacting with intracellular mRNA biomarkers. In the presence of the target gene (e.g., disease biomarker or other control genes), mRNA interacts with the NanoFlare, dislodging (releasing) the reporter flare. Leaving the proximity of the gold nanoparticle core, a strong fluorescence is generated. Without target gene hybridization, fluorescence signal does not appreciably increase but remains below background levels. In the presence of sufficient disease biomarker, fluorescence signal can be superficially acquired.

The authors concluded that NanoFlare technology is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden. This vision of simplifying disease diagnosis using topically applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed. The study was published on April 13, 2018, in the journal Nature Biomedical Engineering.

Related Links:
Nanyang Technological University


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.